Abstracts tagged "SLE"

Abstract Number: 2677 • 2014 ACR/ARHP Annual Meeting
Decreased Levels of SRSF1 (Serin/Arginine-Rich Splicing Factor1) Induced Lower Levels of RasGRP1 in T Cells from Patients with Systemic Lupus Erythematosus
Takashi Kurita¹, Shinsuke Yasuda¹, Vaishali Moulton², Yuka Shimizu¹, Michihito Kono¹, Hideyuki Koide¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, George C. Tsokos³ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Down-regulation of MAP kinase pathway has been recognized in T cells from patients with SLE that results in hypo-methylation of DNA. RasGRP1 is an…
Abstract Number: 1955 • 2014 ACR/ARHP Annual Meeting
Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Monoclonal antibodies (mAbs) targeting B cell antigens CD20 and CD22 are used to treat patients with SLE either in the clinic or in clinical…
Abstract Number: 1611 • 2014 ACR/ARHP Annual Meeting
Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Noémie Jourde-Chiche Sr.¹, Stéphane Burtey², Nathalie Bardin³, Elizabeth Whalen⁴, Bertrand Gondouin⁵, Scott Presnell⁶, Bertrand Dussol⁷, Gilles Kaplanski⁸, Jean-Robert Harle⁹, Yvon Berland², Virginia Pascual¹⁰, Damien Chaussabel⁴ and Laurent Chiche¹¹, ¹Nephrology, Aix-Marseille Université - APHM, Marseille, France, ²Nephrology, APHM, Marseille, France, ³Hopital de la Conception, Marseille, France, ⁴BRI, seattle, WA, ⁵Department of Nephrology, APHM, Marseille, France, ⁶bri, seattle, WA, ⁷AP Marseille, Marseille, France, ⁸INSERM U608, Marseille, France, ⁹Internal Medicine, APHM, Marseille, France, ¹⁰Baylor University, Dallas, TX, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France
Background/Purpose: Lupus nephritis (LN) is a serious complication of SLE. Reliable biomarkers to assess and/or predict renal involvement in SLE patients are needed. The aim…
Abstract Number: 681 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus
Meenakshi Jolly¹, Winston Sequeira², Sarfraz Hasni³, Zulfiqar Ali⁴, Sergio Toloza⁵, Ana M. Bertoli⁶, Ivana Blazevic⁷, Luis M. Vila⁸, Ioana Moldovan⁹, Karina D Torralba¹⁰, Berna Goker¹¹, Josiane Bourré-Tessier¹², S. Navarra¹³, Daniel Wallace¹⁴, Michael H. Weisman¹⁵, Ann E. Clarke¹⁶ and Chi Chiu Mok¹⁷, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University, Chicago, IL, ³NIH, BETHESDA, MD, ⁴NIH, Bethesda, MD, ⁵Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁷University of Buenos Aires, Buenos Aries, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰University of Southern California, LA, CA, ¹¹Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹²Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹³University of Santo Tomas Hospital, Manila, Philippines, ¹⁴UCLA, LA, CA, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁷Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: Hydroxychloroquine (HCQ) has been shown to be beneficial to patients with Systemic Lupus Erythematosus (SLE), however, its effects on the quality of life (QOL)…
Abstract Number: 2662 • 2014 ACR/ARHP Annual Meeting
Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus
Renata Barbosa¹, Karina Oliveira Peliçari², Aline T. Lapa³, Nailu A. Sinicato³, Mariana Postal³, Roberto Marini⁴, Marcelo Govoni Sr.⁵ and Simone Appenzeller⁶, ¹Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, Brazil, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Department of Clinical medicine and Experimental, University of Ferrara, Ferrara, Italy, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is caused by an imbalance of the immune system and may lead to injury and dysfunction of various systems and…
Abstract Number: 1954 • 2014 ACR/ARHP Annual Meeting
Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice
Adriano Taddeo¹, Laleh Khodadadi¹, Qingyu Cheng², Andreas H. Radbruch¹, Falk Hiepe³ and Bimba F. Hoyer², ¹Deutsches Rheumaforschungszentrum, Berlin, Germany, ²Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany
Background/Purpose: Autoantibodies contribute significantly to the pathogenesis of systemic lupus erythematosus (SLE). The long-lived plasma cells (LLPC) secreting such autoantibodies are unfortunately refractory to conventional…
Abstract Number: 1607 • 2014 ACR/ARHP Annual Meeting
B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou² and Mary K. Crow³, ¹Research, HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose Lupus flare reflects an increase of disease activity that is associated with significant morbidity and accumulation of tissue damage. Prediction and prevention of lupus…
Abstract Number: 699 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes
Nimrit Dhillon¹, Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE). The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to…
Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
John A. Reynolds¹, David W. Ray², Terence O'Neill³, Yvonne Alexander⁴ and Ian N. Bruce^5,6, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…
Abstract Number: 1923 • 2014 ACR/ARHP Annual Meeting
Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10
John A. Reynolds¹, David W. Ray², Yvonne Alexander³ and Ian N. Bruce⁴, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose Endothelial repair is important for the maintenance of vascular integrity and is impaired in patients with SLE. Myeloid angiogenic cells (MACs) contribute to endothelial…
Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…
Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
John G. Hanly¹, Amyn Sayani², Steve Doucette³, Sandra Iczkovitz² and Jorge Alfonso Ross², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ³Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
Abstract Number: 2955 • 2014 ACR/ARHP Annual Meeting
The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis
Sarah French¹, Kimberly E. Taylor², Sharon A. Chung¹, Joanne Nitiham³, Michelle Petri⁴, Peter K. Gregersen⁵, Ward Ortmann⁶, Annette T. Lee⁷, Timothy W. Behrens⁶, Susan Manzi⁸, F. Yesim Demirci⁹, M. Ilyas Kamboh¹⁰, Robert R. Graham⁶, Michael F. Seldin¹¹ and Lindsey A. Criswell³, ¹School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Human Genetics, University of Pittsburgh, Pittsburgh, PA, ¹¹Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA
Background/Purpose Lupus nephritis (LN) has a higher prevalence among African Americans, Hispanics, and Asians compared to Caucasians. Significant differences in SLE severity also exist within…
Abstract Number: 2652 • 2014 ACR/ARHP Annual Meeting
Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Anne B Tjensvoll¹, Maria B Lauvsnes², Shunsei Hirohata³, Jan T Kvaløy⁴, Mona K Beyer⁵, Erna Harboe⁶, Lasse G Gøransson⁶, Ole J Greve⁷ and Roald Omdal⁸, ¹Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ²Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁴Research Department, Stavanger University Hospital, Stavanger, Norway, ⁵Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ⁶Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁷Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Headache, especially migraine, is frequent and one of the most common neuropsychiatric manifestations in systemic lupus erythematosus (SLE). A possible mechanism for this is…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].